Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis [0.03%]
三阴性乳腺癌病理完全缓解的术前治疗方案的相关研究：系统评价和网络 Meta 分析
Brenda Luana Rocha Soares Menegat,Ana Luíza Rocha Soares Menegat,Maria Victória Ferreira Piccoli et al.
Brenda Luana Rocha Soares Menegat et al.
Introduction: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving patholo...
Ezra A Bernstein,Jonathan Schoenhals,Shawn Dason et al.
Ezra A Bernstein et al.
Introduction: Nearly 81,000 new cases of renal cell carcinoma are expected to be diagnosed in 2025, with more than one-third of patients presenting with or eventually developing metastatic disease. Some patients develop o...
Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response [0.03%]
可切除胃癌新辅助化疗后生存的影响因素：辅助化疗剂量强度、放疗和病理学缓解程度
Özgecan Dülgar Kaya,Ayberk Bayramgil,Ahmet Bilici et al.
Özgecan Dülgar Kaya et al.
Background: Neoadjuvant chemotherapy (NACT) is the standard of care for locally advanced gastric cancer, but adjuvant therapy is not tailored to pathological response and outcomes are poor. This study evaluated the impact...
A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores [0.03%]
高TDM评分的抗血管生成酪氨酸激酶抑制剂(TKIs)临床药动学和药效学系统评价
Abdul Wasay Sherazi,Muhammad Fawad Rasool,Zheng Jiao et al.
Abdul Wasay Sherazi et al.
Introduction: Tyrosine kinase inhibitor (TKI) drugs are used to treat various cancer types. This systematic review evaluates the published pharmacokinetic (PK) and pharmacodynamic (PD) parameters of TKI drugs with high th...
National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia [0.03%]
哥伦比亚围手术期和局部晚期NSCLC管理的国家德尔菲共识
Ricardo Bruges Maya,Milton Lombana,Carlos Andres Carvajal-Fierro et al.
Ricardo Bruges Maya et al.
Objectives: To develop Colombian, evidence-informed consensus recommendations for perioperative systemic therapy and unresectable stage III non-small cell lung cancer (NSCLC), considering local testing and access constrai...
Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? [0.03%]
低风险的乙型肝炎患者可以考虑停止肝细胞癌监测吗？
Nicole J Kim,H Nina Kim,Brian J McMahon et al.
Nicole J Kim et al.
Introduction: Chronic hepatitis B (CHB) can cause liver cirrhosis and hepatocellular carcinoma (HCC). HCC surveillance with an abdominal ultrasound and serum alpha-fetoprotein every six months is recommended for patients ...
Antibody-drug conjugates in oncology: a clinically focused review for nursing practice [0.03%]
肿瘤学中抗体-药物偶联物的临床应用：护理实践综述
Ioanna Tsatsou,Eleni Panagou,Ourania Govina
Ioanna Tsatsou
Introduction: Antibody-drug conjugates (ADCs) are an expanding class of targeted cancer therapies that combine monoclonal antibody specificity with potent cytotoxic agents, offering improved precision and efficacy across ...
ESMO 2025 and new therapies in breast cancer: does society always benefit? [0.03%]
从ESMO 2025展望乳腺癌新疗法：社会是否总是受益？
Nabil Ismaili
Nabil Ismaili
The ESMO 2025 Congress delivered practice-defining data across breast cancer. Key results included the first overall survival benefit for an adjuvant CDK4/6 inhibitor in high-risk HR+/HER2- early breast cancer and T-DXd established as stand...
Radiotheranostics in solid tumors: focus on radiopharmaceutical therapy and clinical challenges [0.03%]
实体瘤的放疗诊断：放射药物治疗及临床挑战:focus
Daniela Lucente,Stefania Bellino,Anna La Salvia
Daniela Lucente
Introduction: Theranostic radiopharmaceuticals represent a significant advancement in personalized medicine, particularly in oncology. By integrating diagnostic imaging and targeted radionuclide therapy within a single mo...
Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas [0.03%]
症状性Ⅰ型神经纤维瘤病丛状神经纤维瘤的治疗中的米达imetinib疗法
Kester A Phillips,David Schiff
Kester A Phillips
Introduction: Neurofibromatosis type 1 (NF1) is a rare genetic disorder frequently complicated by plexiform neurofibromas (PNs) - benign but often morbid tumors associated with pain, disfigurement, and functional impairme...